Lessons in Laboratory Compliance from a $30 Million Settlement
‘Lean lab’ setup appears to have caught the eyes of investigators
‘Lean lab’ setup appears to have caught the eyes of investigators
How clinical laboratories should prepare for the next wave of oversight in the new year
The $14.6 billion bust by federal prosecutors shows gaps that every laboratory should monitor
Read this overview of legislation and regulations governing laboratory marketing practices and learn tips to ensure these activities remain compliant
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
These three lab testing areas were the main sources of fraud and abuse revealed in the OIG’s latest Semi-Annual Report to Congress.
Current genetic testing enforcement trends and what you can do to minimize the liability risks of your lab.
At $1.1 billion, total recoveries in 2022 did exceed $1 billion for the fourth year in a row, but dropped from $1.7 billion in FY 2021